LuMind IDSC joins Advocacy Day on Capitol Hill
In April, leaders from LuMind IDSC joined with 350 self-advocates, caregivers, and professionals to meet with federal legislators in a
May 12, 2023
In April, leaders from LuMind IDSC joined with 350 self-advocates, caregivers, and professionals to meet with federal legislators in a
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves their anti-amyloid drug, donanemab, significantly
At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve Stimulator for children with Down
“Alzheimer’s meds are here. But for the Down syndrome community, it’s still the 1980s” by Annalee Armstrong, Fierce Biotech An
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research organization, announced a new collaboration
Dear Friend of LuMind IDSC, Recently, I spoke with a family whose newborn baby had heart surgery. As many of
On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for lecanemab, an anti-amyloid drug to
Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for an antibody drug candidate called
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and